1. Home
  2. SRL vs ENTX Comparison

SRL vs ENTX Comparison

Compare SRL & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scully Royalty Ltd.

SRL

Scully Royalty Ltd.

HOLD

Current Price

$9.01

Market Cap

83.0M

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.40

Market Cap

74.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRL
ENTX
Founded
2017
2010
Country
China
Israel
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.0M
74.7M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
SRL
ENTX
Price
$9.01
$1.40
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
35.6K
264.8K
Earning Date
04-24-2026
11-14-2025
Dividend Yield
11.49%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$26,224,099.00
$124,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
25.25
52 Week Low
$5.13
$1.44
52 Week High
$9.64
$3.22

Technical Indicators

Market Signals
Indicator
SRL
ENTX
Relative Strength Index (RSI) 62.12 32.54
Support Level $8.78 $1.52
Resistance Level $9.45 $1.59
Average True Range (ATR) 0.57 0.13
MACD 0.02 0.00
Stochastic Oscillator 74.20 0.00

Price Performance

Historical Comparison
SRL
ENTX

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: